Genor Biopharma Holdings Limited (6998.HK)
HKD 1.66
(-5.68%)
HKD 1.66
(-5.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | 15.93 Million | - | 10.33 Million | 13.03 Million | 6.88 Million |
| Cost of Revenue | - | 983 Thousand | - | 2.59 Million | 9.56 Million | 5.45 Million |
| Gross Profit | - | 14.94 Million | - | 7.73 Million | 3.47 Million | 1.43 Million |
| Operating Expenses | 711.19 Million | 801.15 Million | 899.51 Million | 932.15 Million | 518.44 Million | 281.61 Million |
| Selling, General and Administrative Expenses | 125.23 Million | 217.27 Million | 305.95 Million | 241.44 Million | 14.04 Million | 7.34 Million |
| Research and Development Expenses | 564.27 Million | 583.88 Million | 612.71 Million | 696.57 Million | 438.81 Million | 271.49 Million |
| Other Expenses | 21.68 Million | 3.48 Million | -19.15 Million | -5.85 Million | 65.58 Million | 2.77 Million |
| Cost and Expenses | 711.19 Million | 802.13 Million | 899.51 Million | 934.75 Million | 528 Million | 287.07 Million |
| Operating Income | -711.19 Million | -786.2 Million | -859.1 Million | -924.42 Million | -514.97 Million | -280.18 Million |
| Interest Expense | - | 2.85 Million | 2.36 Million | 5.53 Million | 2.09 Million | 7.04 Million |
| Income Tax Expense | 2.28 Million | -2.02 Million | -932 Thousand | -5.8 Million | -891 Thousand | 1.53 Million |
| Earnings before Tax | -677.49 Million | -732.42 Million | -866.3 Million | -3.03 Billion | -523.63 Million | -288.07 Million |
| Net Income | -674.36 Million | -730.39 Million | -865.37 Million | -3.03 Billion | -522.74 Million | -289.61 Million |
| Earnings Per Share Basic | -1.33 | -1.45 | -1.75 | -12.37 | -1.09 | -0.60 |
| Earnings Per Share Diluted | -1.33 | -1.45 | -1.74 | -12.37 | -1.09 | -0.60 |
| Weighted Average Shares Outstanding | 506.24 Million | 504.3 Million | 495.18 Million | 244.89 Million | 481.09 Million | 481.09 Million |
| Weighted Average Shares Outstanding (Diluted) | 506.24 Million | 504.81 Million | 496.2 Million | 244.89 Million | 481.09 Million | 481.09 Million |
| Gross Margin | - | 0.94 | - | 0.75 | 0.27 | 0.21 |
| EBIT Margin | - | -42.42 | - | -288.43 | -36.77 | -35.21 |
| Profit Margin | - | -45.84 | - | -293.34 | -40.09 | -42.08 |
| EBITDA | -551 Million | -675.88 Million | -819.5 Million | -2.98 Billion | -480.91 Million | -243.85 Million |
| Earnings Before Tax Margin | - | -49.35 | - | -89.48 | -39.49 | -40.71 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 7.23 Million | 7.23 Million | - | - | - | - |
| Cost of Revenue | 174.5 Thousand | 174.5 Thousand | - | - | - | 31.37 Million |
| Gross Profit | 7.06 Million | 7.06 Million | - | - | - | -31.37 Million |
| Operating Expenses | 72.09 Million | 72.09 Million | 706.27 Million | 207.7 Million | 205.24 Million | 147.89 Million |
| Selling, General and Administrative Expenses | 19.27 Million | 19.27 Million | - | 26.29 Million | 26.29 Million | 36.32 Million |
| Research and Development Expenses | 54.84 Million | 54.84 Million | - | 169.75 Million | 169.75 Million | 112.38 Million |
| Other Expenses | -2.01 Million | -2.01 Million | - | 11.65 Million | - | - |
| Cost and Expenses | 72.27 Million | 72.27 Million | 706.27 Million | 207.7 Million | 205.24 Million | 147.89 Million |
| Operating Income | -65.03 Million | -65.03 Million | -616.29 Million | -207.7 Million | -164.67 Million | -143.47 Million |
| Interest Expense | - | - | - | - | - | 748.69 Thousand |
| Income Tax Expense | 640.5 Thousand | 640.5 Thousand | 2.28 Million | 581.5 Thousand | 581.5 Thousand | 558.5 Thousand |
| Earnings before Tax | -63.78 Million | -63.78 Million | -677.49 Million | -200.66 Million | -200.66 Million | -138.08 Million |
| Net Income | -62.84 Million | -62.84 Million | -674.36 Million | -199.9 Million | -199.9 Million | -137.27 Million |
| Earnings Per Share Basic | -0.12 | -0.12 | - | -0.39 | -0.39 | -0.27 |
| Earnings Per Share Diluted | -0.12 | -0.12 | - | -0.39 | -0.39 | -0.27 |
| Weighted Average Shares Outstanding | 502.78 Million | 502.78 Million | 506.24 Million | 506.73 Million | 506.73 Million | 505.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 509.67 Million | 509.67 Million | 506.24 Million | 506.73 Million | 506.73 Million | 505.75 Million |
| Gross Margin | 0.98 | 0.98 | - | - | - | - |
| EBIT Margin | -6.09 | -6.09 | - | - | - | - |
| Profit Margin | -8.69 | -8.69 | - | - | - | - |
| EBITDA | -44.07 Million | -44.07 Million | - | -143.95 Million | -143.95 Million | -131.54 Million |
| Earnings Before Tax Margin | -8.99 | -8.99 | - | - | - | - |
EVTZF
AXISCADES
SOUTHERNIN
GLENMARK
ACOGF
STEL